Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
30 sept. 2024 07h00 HE | Vor Biopharma
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new...
AB Science fait aujo
AB Science fait aujourd'hui le point sur le programme microtubule AB8939 et en particulier sur la capacité d'AB8939 à générer une réponse sur le réarrangement du gène MECOM
26 sept. 2024 02h28 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LE PROGRAMME MICROTUBULE AB8939 ET EN PARTICULIER SUR LA CAPACITÉ D’AB8939 À GÉNÉRER UNE RÉPONSE SUR LE REARRANGEMENT DU GENE MECOM Paris, 26...
AB Science provides
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
26 sept. 2024 02h28 HE | AB Science
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET...
Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE | Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
Q Assist brings generative AI capabilities to Quantexa’s Decision Intelligence Platform.
Quantexa Recognized as Leader in Enterprise and Payment Fraud Solutions in the 2024 Chartis RiskTech Quadrant® For Enterprise Fraud Solutions
09 sept. 2024 06h41 HE | Quantexa
Quantexa Recognized as Leader in Enterprise and Payment Fraud Solutions in the 2024 Chartis RiskTech Quadrant® For Enterprise Fraud Solutions
Vor-Wordmark-RGB-FullColor-070920.png
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
05 sept. 2024 16h01 HE | Vor Biopharma
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Quantexa-logo-positive-RGB.png
Quantexa Recognized as a “Luminary” in Celent’s 2024 Insurance Fraud Detection Solutions Report
04 sept. 2024 05h32 HE | Quantexa
Quantexa announced that its Fraud Detection solution has been awarded “Luminary” status in Celent’s 2024 Insurance Fraud Detection Solutions Report.
SentiBioLogo.jpg
Senti Bio to Participate in Upcoming Investor Conferences
03 sept. 2024 08h15 HE | Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
28 août 2024 08h00 HE | Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
SentiBioLogo.jpg
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
13 août 2024 16h05 HE | Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...